The State announced on the night of Sunday, October 20, that it had found a “tripartite agreement” with the pharmaceutical group Sanofi and the US fund CD&R for the sale of the subsidiary of the non-prescription pharmaceutical group Opella, which markets Doliprane.
“We have obtained guarantees for the maintenance and development of Opella in France. Our demands regarding employment, production and investment will be respected. For Doliprane and other essential medicines in the country »wrote the Minister of Economy, Antoine Armand, on Sunday, October 20, evening.
“The State, through Bpifrance, will be a shareholder to guarantee it”he added, seeming to give the green light to this possible transfer. “We have achieved the highest level of guarantees possible in the discussions” with Sanofi on this issue, the offices of the Ministers of Economy and Industry informed the press.
The contributions area is reserved for subscribers.
Subscribe to access this discussion space and contribute to the discussion.
Contribute
Reuse this content
